About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, September 26th, 2014

The QualityStocks
Daily Stock List


GrowBLOX Sciences, Inc. (GBLX)

Wall St Report, Wall Street Resources, Pumps and Dumps, Investor News Source, TradeThesePicks, AskSlapper, Equities IR, and Investor-Advantage.com reported on GrowBLOX Sciences, Inc. (GBLX), and we choose to report on the Company also, here at the QualityStocks Daily Newsletter.

GrowBLOX Sciences, Inc. is a biotechnology and research company with headquarters in Las Vegas, Nevada. It has developed proprietary indoor growing chambers precisely designed for medical cannabis cultivation. The Company is working to set the standard for manufacturing medical cannabis producing technology, and discovering, developing, and commercializing proprietary strains of cannabis to treat a broad array of serious medical conditions. GrowBLOX Sciences lists on the OTCQB.

On March 12, 2014, GrowBLOX entered into an asset acquisition agreement that took the Company to the vanguard of the emerging legal cannabis industry. The March agreement gave GrowBLOX intellectual property (IP), equipment, business plans, and other assets that it believes will allow it to transform its industry through turning cannabis cultivation from an art into a science.

Its GrowBLOX chamber allows for completely controlled growing conditions. As a result, this ensures the manufacture of a consistent, toxin-free, natural and medicinal-grade product. The Company believes that the advantages of a controlled environment over traditional outdoor or greenhouse growing will embolden the public, nutraceutical, and pharmaceutical industries to embrace cannabis as an effective treatment for a multitude of serious medical conditions.

The GrowBLOX™ Controlled Environment Agricultural Chambers (GrowBLOX™) is the first chamber of its kind with the ability to monitor and control the growth process to produce high-grade medicinal marijuana. Concerning its GrowBLOX™ Nutrient System, the Company provides growers with premium blends of nutrients containing 100 percent natural water-soluble nutrients designed for use with its advanced AeroVAPOR™ misting system.

GrowBLOX Sciences’ formulas contain all the essential minerals cannabis plants need for optimal growth. Its intelligent control system ensures that growers know the optimal time, quantity, and kind of nutrients to add to the AeroVAPOR™ unit. This eliminates any guesswork.

The full GrowBLOX Solution contains the GrowBLOXTM tissue propagation chamber for preparing clonally-derived plants; the original GrowBLOXTM growing chamber; the GrowBLOXTM curing chamber to cure and dry each Cannabis harvest; the GrowBLOXTMextraction chamber to create the Company’s proprietary oils; GrowBLOXTM branded, childproof packaging for each of the GrowBLOX strains and cannabis-oil based products; and GrowBLOX research supporting the medical efficacy of its products. 

GrowBLOX Sciences, Inc. (GBLX), closed Friday's trading session at $0.92, up 0.55%, on 66,640 volume with 48 trades. The average volume for the last 60 days is 120,091 and the stock's 52-week low/high is $0.30/$8.90.

iHookup Social, Inc. (HKUP)

Today we are reporting on iHookup Social, Inc. (HKUP), here at the QualityStocks Daily Newsletter.

iHookup Social, Inc. is a mobile application positioned at the intersection of dating, social media, and location-based connections. The Company is a "proximity based" mobile social platform, which enables real connections, between real people, in real time. It employs the intelligence of GPS and localized recommendations for dating, friends, groups and organizations to break through closed social cliques and expand them virtually, as well as in real life. iHookup Social lists on the OTC Markets’ OTCQB. The company has its headquarters in Campbell, California.

Its users will be provided with "local" options of many types, allowing mobile distribution of locally relevant content and special offers. iHookup Social’s intention is to bring together an active opportunity for brands, advertisers and merchants to interact in new and ground-breaking ways with the iHookup Social Network. This is while building customer loyalty, engagement, and revenues. iHookup Social is pursuing its growth in its current "dating vertical" market. It is also expanding its reach in the general audience category of "Social Networking."

In early September, iHookup Social provided user growth statistics for August 2014. For the month of August, it showed growth over the prior month of July with a total of 86,207 new downloads of the iHookup Social app in the Apple App Store marketplace. This total is another record for iHookup Social, which has now exceeded 350,000 registered users.

In addition, this month, iHookup Social announced its integration initiative to release a streamlined version of its iHookup app to be compatible with "Apple Watch TM," which was announced September 9, 2014 during Apple's annual "Apple Key Note" address.

This week, iHookup Social announced that it has retained Megacast to market the Company's popular app and assist it in the investment community. Megacast is a digital branding and advertising agency. It has exclusive expertise in Branding & Design, Content Creation, Viral Marketing and Distribution.

Mr. Robert Rositano Jr., Chief Executive Officer of iHookup Social, said, "We are excited to begin an engagement with Megacast which we see as a perfect fit to simultaneously market our popular dating app to an expanded audience and to increase visibility for our corporate story."

iHookup Social, Inc. (HKUP), closed Friday's trading session at $0.0039, down 2.50%, on 1,621,905 volume with 40 trades. The average volume for the last 60 days is 1,490,843 and the stock's 52-week low/high is $0.0033/$0.676.

Adaptive Medias, Inc. (ADTM)

SmallCapVoice, Bull Warrior Stocks, AnotherWinningTrade, The Best Newsletters, Market FN, OTCPicks, Stockoutlaws, Forbes, PennyTrader Publisher, Wyatt Investment Research, Stealth Stocks, and Hidden Values Alert reported previously on Adaptive Medias, Inc. (ADTM), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Adaptive Medias, Inc. is a content syndication and monetization company whose shares trade on the OTC Markets’ OTCQB. The Company is a programmatic audience and content monetization provider for website owners, application (app) developers and video publishers who want to more effectively optimize content via advertising. Adaptive Medias has its head office in Irvine, California.

The Company provides a foundation for publishers and developers looking to engage brand advertisers by way of a multi-channel approach, which delivers integrated, engaging, as well as impactful ads across multiple devices. Adaptive Media meets the needs of its publishers with a focus on maintaining user experience. This is while delivering well-timed and relevant ads via its multi-channel ad delivery and content platform.

Regarding Networks, Adaptive Medias makes it easy for website publishers to connect with quality advertisers and get rewarded for propelling conversions. Its network partners’ work closely with its team to ensure publisher inventory is evaluated fast and available for purchase. Regarding Content Providers, the Company offers content providers customized solutions, which deliver first-rate monetization for their partners’ web sites.

Last week, Adaptive Medias announced that it closed private placements with two institutional investors. It agreed to sell a total of 2.13 million shares of its common stock at $2.25 per share, for total gross proceeds of $5.2 million. Adaptive Medias’ intention is to use the total net proceeds from the transaction to assertively expand its customer acquisition through accelerated sales and marketing efforts, as well as for other general corporate purposes.

In addition, last week, Adaptive Medias announced the launch of its Media Graph platform. Media Graph is its flagship product offering. It provides publishers, producers, and advertisers the ability to easily and effectively monetize digital video content across all screens and devices through one centralized solution.

Media Graph provides easy content ingestion and campaign setup; less reliance on multiple vendors; strong advertisement serving and cross-screen capabilities, and real-time campaign management. All platform users get access to an easy-to-navigate platform, an HTML5/Flash friendly custom video player designed for any device, express publishing capabilities, and encoding, video streaming and hosting services. Additionally, users get access to more than 1 million pieces of premium video content available for syndication across all devices.

Adaptive Medias, Inc. (ADTM), closed Friday's trading session at $3.85, up 10.00%, on 122,190 volume with 123 trades. The average volume for the last 60 days is 12,427 and the stock's 52-week low/high is $1.70/$4.4745.

HyperSolar, Inc. (HYSR)

TopPennyStockMovers, The MicrocapNews, and AimHighProfits reported earlier on HyperSolar, Inc. (HYSR), and we highlight the Company today, here at the QualityStocks Daily Newsletter.

OTCQB-listed HyperSolar, Inc. is developing a unique, low cost technology to make renewable hydrogen using sunlight and any source of water. This includes seawater and wastewater. The Company’s solution is the HyperSolar H2Generator™. Its solar hydrogen generator eliminates the need for conventional electrolyzers. HyperSolar has its corporate office in Santa Barbara, California.

Hydrogen fuel usage produces pure water as the only by-product. Through optimizing the science of water electrolysis at the nano-level, HyperSolar’s low cost nanoparticles mimic photosynthesis to efficiently use sunlight to separate hydrogen from water, to produce environmentally friendly renewable hydrogen. Its research focuses on developing a low-cost and submersible hydrogen production particle that can split water molecules under the sun, imitating the central functions of photosynthesis. Each particle is a complete hydrogen generator, which contains a novel high voltage solar cell bonded to chemical catalysts by a proprietary encapsulation coating.

HyperSolar H2Generator™ Panels can be connected together to scale to any size system to meet application specific hydrogen requirements. The Company’s intention, using its low cost method to produce renewable hydrogen, is to enable a world of distributed hydrogen production for renewable electricity and hydrogen fuel cell vehicles.

HyperSolar announced earlier this year that its artificial photosynthesis technology can now produce 1.2 volt open circuit voltage for use in direct solar hydrogen production. This achievement represents another 10 percent increase over the prior 1.1 volt reached late last year. 

HyperSolar announced in March 2014 that it jointly filed a patent application with the University of California, Santa Barbara (UCSB) for the "method of manufacture of multi-junction artificial photosynthetic cells." The patent application claims a novel low cost and high voltage multi-junction solar cell made from a single material. The single material has a low cost per watt. The voltage realized so far in the laboratory is very close to the critical 1.5 volts needed for splitting water molecules into hydrogen and oxygen.

This week, HyperSolar commented on the recent debut of the 2015 Toyota FCV. This is a sedan which runs on hydrogen power. The expectation is that the Toyota FCV will reach dealerships in the middle of 2015.

Mr. Tim Young, HyperSolar Chief Executive officer, said, ""Toyota and other auto manufacturers' commitment to hydrogen fuel cell technology further underscores HyperSolar's opportunity in the market. As these vehicles are adopted by the masses and require refueling not just throughout California but the entire country, we believe that HyperSolar's ability to produce hydrogen at or near the point of distribution via a renewable process will provide fueling stations with the support needed to meet consumer demand."

HyperSolar, Inc. (HYSR), closed Friday's trading session at $0.0184, down 3.16%, on 1,205,080 volume with 54 trades. The average volume for the last 60 days is 3,368,308 and the stock's 52-week low/high is $0.0035/$0.1345.

INVENT Ventures, Inc. (IDEA)

Bull Trends, PennyStocks24, Pumps and Dumps, Club Penny Stocks Network, First Penny Picks, StocksImpossible, and OTCBB Journal reported earlier on INVENT Ventures, Inc. (IDEA), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

INVENT Ventures, Inc. is a technology venture fund that lists on the OTCQB. It builds, manages, and invests in early-stage web and mobile technology companies. It supplies portfolio companies with the capital to nurture its initial product, and provides practical support services to lessen start-up costs and accelerate time to market. The Company develops businesses in the consumer Internet, mobile and biotechnology markets. INVENT Ventures’ has its headquarters in Santa Monica, California.

The Company’s process maximizes efficiencies in how companies are conceived, built, and brought to market. INVENT’s structure provides all of its stakeholders with access to early stage venture capital through its curated and actively managed portfolio of technology businesses. INVENT Ventures owns six companies at different stages of development. Its services include product development and design, corporate formation and structure, and exposure to additional financing. INVENT Ventures builds initial prototypes, crafts teams around each idea, and provides access to capital.

The Company announced previously that its portfolio company Stockr, Inc. received an investment from STAR Angel Network. Stockr is a modern social network. It connects investors to each other, to investor relations departments at public companies, and to industry experts. STAR Angel Network is a New York City-based Angel network consisting of professional athletes and business leaders. Stockr provides a specialized platform where investors, analysts, and public companies can communicate transparently and directly concerning financial news, stocks, market trends, investment ideas, and more. 

INVENT Ventures announced this past May that its portfolio company Sanguine Biosciences, Inc. secured an agreement with Mayo Clinic Bioservices. With this agreement, Mayo Clinic Bioservices will process, store and ship biospecimens collected by Sanguine Biosciences for the purpose of developing new therapies. Mayo Clinic Bioservices will provide integrated laboratory services.

INVENT Ventures announced in June that its portfolio company, VIRURL, Inc. entered into a Letter of Intent (LOI) with Revenue.com Corp., a Nevada corporation focused on acquiring best in class advertising platforms. VIRURL is a native advertising company developing advertising technology to connect content owners with a targeted audience on the web.

Moreover, this month, INVENT Ventures announced that Revenue.com is ranked #2 in Content Marketing & Native Advertising market share by Leadledger.com.  A sales intelligence platform that helps technology sales & marketing professionals monitor market share, Leadledger.com states that "Content marketing and native advertising is a type of advertising in which advertising content is integrated on a page with news or editorial content. As marketers work to improve relevance and communicate with customers in a world crowded with advertisements, native advertising provides an incredible opportunity to gain brand exposure with content while driving relevant, qualified traffic." Revenue.com is developed, owned and operated by VIRURL, Inc., a portfolio company incubated by INVENT Ventures.

INVENT Ventures, Inc. (IDEA), closed Friday's trading session at $0.10, even for the day. The average volume for the last 60 days is 9,644 and the stock's 52-week low/high is $0.10/$0.40.

First Choice Healthcare Solutions, Inc. (FCHS)

Greenbackers, TheMicrocapNews, PennyStockSpy, 007 Stock Chat, StocksImpossible, First Penny Picks and OTCBB Journal reported this month on First Choice Healthcare Solutions, Inc. (FCHS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

First Choice Healthcare Solutions, Inc. (FCHS) engages in owning and operating multi-specialty medical centers of excellence throughout the southeastern U.S. Its commitment is to delivering clinically superior, patient-centric care. The Company operates its different businesses by way of its wholly-owned subsidiaries, FCID Medical, Inc. and FCID Holdings, Inc. FCHS is based in Melbourne, Florida. The Company lists on the OTCQB.

FCID Medical has acquired First Choice Medical Group of Brevard, LLC. First Choice Medical Group is a multispecialty medical group specializing in Orthopedics, Neurology and Pain Management. Via FCID Medical, the Company operates its flagship center, First Choice Medical Group, which specializes in the delivery of musculoskeletal medicine and rehabilitative care. FCHS' commercial real estate interests, which house its medical centers of excellence, are managed by FCID Holdings.

The foundation of the FCID Medical business plan is to develop and acquire efficient, specialized healthcare clinical units. The professional medical clinical units include an optimum mix of synergistic multi-specialty physicians combined with an array of diagnostic capabilities.

Pertaining to FCHS’ Real Estate Division facilities, the Company has its Marina Towers, LLC. Marina Towers is a Class A, 68,000 sq. ft., five story office building on the Indian River in Melbourne, Florida. This building is home to tenants such as UBS Financial, Support Systems and Modus Operandi. The building is also home to First Choice Medical Group.

Last month, FCHS announced its Q2 financial results for the three and six months ended June 30, 2014. The Company had a 43 percent increase in total revenue to $2,107,164 for Q2 2014, versus $1,469,570 for Q2 2013. This was driven by growth in net patient service revenue from the Medical Center of Excellence, FCMG.

For Q2, its wholly-owned subsidiary (Medical Division), First Choice Medical Group of Brevard, experienced a 53 percent increase in revenue to $1,848,441 from $1,208,813 for Q2 2013 in its Medical Center of Excellence. For Q2, net loss was $(448,571), or $0.03 per share. This is in comparison to a net loss of $(120,392), or $0.01 loss per share, for Q2 2013.

First Choice Healthcare Solutions, Inc. (FCHS), closed Friday's trading session at $1.11, down 5.13%, on 10,100 volume with 4 trades. The average volume for the last 60 days is 15,811 and the stock's 52-week low/high is $0.67/$3.70.

Centrue Financial Corp. (CFCB)

Today we are reporting on Centrue Financial Corp. (CFCB), here at the QualityStocks Daily Newsletter.

Founded in 1982, Centrue Financial Corp. is the parent company of Centrue Bank. Centrue Financial is a regional financial services company with its corporate headquarters in Ottawa, Illinois. It serves a market area that extends from the far western and southern suburbs of the Chicago metropolitan area across Central Illinois down to the metropolitan St. Louis area. Centrue Financial’s shares trade on the OTC Markets’ OTCQB.

Centrue Financial has 24 locations and it has total assets of around $890 million, total loans of $580 million, and total deposits of $770 million. Its Centrue Bank provides commercial and retail banking services to individual and corporate customers. The Bank accepts diverse deposit products. These include checking accounts, business savings accounts, money market accounts, business certificates of deposit, and demand and time deposits.

Centrue Bank’s loan portfolio consists of commercial real estate loans and construction loans; commercial loans; 1-4 family residential real estate and home equity loans, and consumer loans. In addition, it consists of lines of credit, equipment and machinery financing; farm real estate loans; and government lending programs. The Bank additionally offers mortgage banking, brokerage, asset management, and trust services, as well as debit and credit cards.

In August, Centrue Financial announced Q2 2014 results. Net income was $374,000 versus net income of $558,000 in Q1 2014 and a net loss of $309,000 for Q4 2013. The Company sold a financial asset for $750,000 in Q1 2014. Its principal subsidiary, Centrue Bank, had net income of $674,000 for Q2 2014, versus net income of $112,000 in Q1 2014.

Centrue Financial President & Chief Executive Officer, Mr. Kurt R. Stevenson stated, "The second quarter built onto our success from the first quarter as loans continued to grow while seeing meaningful improvement in the Company's asset quality. Quality earnings also were strengthened as core noninterest income items were improved during the quarter and noninterest expenses were well controlled."

Moreover, in August, Centrue Financial announced that it entered into a stock purchase agreement with certain affiliates of Capital Z Partners III, L.P. as lead investor of a proposed capital raise of a total $75 million, or 187,500,000 shares of common stock at a price of $0.40 per share. The agreement intends that Cap Z will own 24.0 percent of Centrue Financial's outstanding common stock after the transaction is complete.

Centrue Financial Corp. (CFCB), closed Friday's trading session at $0.55, down 0.43%, on 4,216 volume with 5 trades. The average volume for the last 60 days is 5,124 and the stock's 52-week low/high is $0.4551/$1.34.


The QualityStocks
Company Corner


Cannabics Pharmaceuticals, Inc. (CNBX)

The QualityStocks Daily Newsletter would like to spotlight Cannabics Pharmaceuticals, Inc. (CNBX). Today, Cannabics Pharmaceuticals, Inc. closed trading at $0.2888, up 15.47%, on 9,978 volume with 10 trades. The stock’s average daily volume over the past 60 days is 11,820, and its 52-week low/high is $0.03/$1.40.

Cannabics Pharmaceuticals, Inc. announced today that it has achieved Good Manufacturing Practices (GMP) capabilities as the Company moves toward the launch of its first clinical study of Cannabics SR capsules. Advancing on its goal to be one of the first and few companies in the world to commercialize clinically tested cannabis-based products, Cannabics intends to launch a series of clinical studies in leading medical centers in Israel where the Company's R&D division is strategically located.

Cannabics Pharmaceuticals, Inc. (CNBX) was founded in 2012 by a team of experts in the fields of molecular biology, cancer research and pharmacology, who recognized the potential of cannabinoid-based therapies for debilitating and incurable ailments. Through the course of its research, the company’s pharmacology team has amassed valuable knowledge in the development of advanced delivery systems for active cannabinoids that provide improved treatment options for patients wishing to utilize the unique medical properties of the cannabis plant.

Leveraging this expertise and knowledge, Cannabics Pharmaceuticals has created a wide range of solutions for standardized, reproducible and easily administered medical cannabis therapies. The company’s flagship product, Cannabics SR, contains a pure concentrate of cannabinoids derived from select cannabis strains, embedded in a sophisticated formulation which provides beneficial therapeutic effects for 10-12 hours upon a single oral administration.

The excipients of the proprietary Cannabics SR formulation are all certified food-grade ingredients and are free of artificial additives or chemical substances. Cannabics’ proprietary technologies are developed in certified laboratories and are licensed to certified manufacturers and distributors with adequate licenses in their local territories. Cannabics Pharmaceuticals itself does not manufacture, distribute, dispense or possess any controlled substances, including cannabis and cannabis-based preparations.

Co-founders Dr. Zohar Koren (CEO) and Dr. Eyal Ballan (CTO) guide the company’s operations with vast experience in business and pharmaceutical development, strategic consulting, venture capital, evolutionary and environmental sciences, anti-cancer drug development and molecular biology. Under their leadership, Cannabics Pharmaceuticals continues to develop its genetic and phenotipic database to provide superior treatments for incapacitating ailments for which there is no cure. Disclaimer

Cannabics Pharmaceuticals, Inc. Company Blog

Cannabics Pharmaceuticals, Inc. News:

Cannabics Pharmaceuticals, Inc. (CNBX) Attains GMP Compliance, Prepares for First Clinical Study of Cannabics SR

Cannabics Pharmaceuticals recruits two former senior Teva Executives to its Advisory Board

Cannabics Pharmaceuticals Inc. (CNBX) Focused on Developing Cannabinoid-based Therapies

WRIT Media Group, Inc. (WRIT)

The QualityStocks Daily Newsletter would like to spotlight WRIT Media Group, Inc. (WRIT). Today, WRIT Media Group, Inc. closed trading at $0.0237, even for the day, on 5,506 volume with 3 trades. The stock’s average daily volume over the past 60 days is 39,498, and its 52-week low/high is $0.015/$0.50.

WRIT Media Group, Inc. wholly-owned subsidiary Retro Infinity Inc. and publisher of classic video games on today's mobile devices, including the Amiga Games brand, announced today that it will launch its online point of sale platforms; www.RetroInfinity.com and www.AmigaGamesInc.com, in conjunction with the first RWR Retro Infinity "Drive to Championship Weekend" NASCAR race. On Saturday, September 27th, Retro Infinity and Amiga Games will launch their online stores, which will market their "retro" gaming titles directly to consumers.

WRIT Media Group, Inc. (WRIT) is focused on expanding in the digital media industry. The holding company currently operates under two different divisions: content creation via Front Row Networks, and "retro" video gaming via Retro Infinity Inc. and Amiga Games Inc.

The company’s Front Row Networks subsidiary produces, acquires and distributes live concerts in 2D and 3D format for initial worldwide digital broadcast into digitally-enabled movie theaters. In addition to presenting live concerts to massive audiences at lower ticket prices, Front Row Networks will license the content for many different distribution channels and sell merchandize where the live concerts are exhibited. The subsidiary also secures and distributes non-concert alternative theatrical programming and aims to acquire the broadest range of rights for exclusive programming.

Retro Infinity specializes in licensing classic computer and console video game libraries and adapts and republishes the most popular titles for smartphones, modern game consoles, micro-consoles, PCs, and tablets. The company leverages platform and classic game brands, coupled with proprietary technologies, to create new revenue from dormant game libraries.

Amiga Games Inc. shares resources with Retro Infinity to adapt and republish the most popular titles from the Amiga family of computers for smartphones, modern game consoles, micro-consoles, PCs, and tablets. WRIT Media Group leverages the Amiga brand along with game brands of the past and proprietary technologies to create new revenue from classic games that have proven their ability to sell very well.

Together with its subsidiaries, WRIT Media Group is well positioned to benefit from the market growth and increased demand for alternative theatrical, mobile, and interactive content. Disclaimer

WRIT Media Group, Inc. Company Blog

WRIT Media Group, Inc. News:

WRIT Media Announces Launch of Online Video Game Point of Sale Platforms

WRIT Media Announces Schedule for NASCAR On-Car and Driver Logo Branding

WRIT Media Retains Digney & Company as Public Relations Agency

Big Tree Group, Inc. (BIGG)

The QualityStocks Daily Newsletter would like to spotlight Big Tree Group, Inc. (BIGG). Today, Big Tree Group, Inc. closed trading at $0.0078, up 8.33%, on 2,734,041 volume with 44 trades. The stock’s average daily volume over the past 60 days is 2,377,906, and its 52-week low/high is $0.006/$0.45.

Big Tree Group, Inc. (BIGG) is an authorized sales agent for thousands of toy manufacturers in China, providing multiple procurement services for international toy distributors and wholesalers. Headquartered in Shantou City, known as the Toy Capital of the world, Big Tree operates a 21,000-square-foot showroom to display its products to thousands of international toy purchasers. The sprawling facility includes an onsite testing laboratory where all toys undergo rigorous testing to ensure both quality and function before reaching the showroom floor.

Big Tree is a “one-stop-shop” for the international sourcing and distribution of toys and other related products. As an authorized agent, Big Tree currently represents more than 8,000 toy manufacturers, offering more than 300,000 varieties of toy products such as remote control toys, digital toys, sports toys, play sets, educational toys, dolls and infant toys. Big Tree conducts its operations through its two fully operating subsidiaries, Big Tree Brunei and Big Tree Shantou.

In 2011, Big Tree began selling its own patented construction toy, the Magic Puzzle (3D). The proprietary Big Tree Magic Puzzle is promoted and distributed solely in the Chinese domestic market, available through Big Tree Shantou’s online store and at several retail locations. The product has been well-received, and Big Tree is also evaluating global marketing and distribution of the Magic Puzzle.

Big Tree’s operations are spearheaded by long-time China toy industry veteran and company CEO Wei Lin, who founded the toy export and import company Shantou Dashu Toy Corp. Ltd. He is supported by a seasoned and experienced management team proficient in operations management, marketing, sales, team management, education and accounting. This leadership team has established an aggressive growth strategy to expand Big Tree’s sales and global product distribution by utilizing its expansive multi-lingual sales team and by leveraging industry contacts to identify strategic mergers and acquisitions, and maximize trade and industry opportunities.

As the world’s leading toy manufacturer and exporter, China produces and distributes two-thirds of the multi-billion dollar toy industry’s global demand. The nation’s manufacturing is highly regional, with 70 percent of toy sales in China generated in the Guangdong province. Strategically located in this province, Big Tree has cultivated an extensive customer base in Asia and Europe and is planning global expansion and distribution, especially in the Americas. Disclaimer

Big Tree Group, Inc. Company Blog

Big Tree Group, Inc. News:

Market Advisors, Inc. Issues Report on Big Tree Group

Big Tree Group Launches New Domestic Online Ecommerce Platform

Big Tree Group Receives Purchase Orders from Costa Rican Retail Chain Valued at Approximately $400,000

Zenosense, Inc. (ZENO)

The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO). Today, Zenosense, Inc. closed trading at $0.38, up 0.03%, on 147,133 volume with 53 trades. The stock’s average daily volume over the past 60 days is 57,911, and its 52-week low/high is $0.15/$1.00.

Zenosense, Inc. (ZENO) is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.

Early detection of MRSA and HAIs in general is vital. Recent studies suggest that implementing prevention practices can lead to up to a 70 percent reduction in certain HAIs with a financial benefit of using these prevention practices estimated to be as high as $25.0 billion to $31.5 billion in medical cost savings in the United States alone (according to a report by the Centers for Disease Control and Prevention, part of the US Department of Health and Human Sciences). Currently, no cost effective early detection device is available.

The Zenosense MRSA detection device is expected to act like a “smoke detector” for MRSA; designed to detect MRSA in the environment or infected patient, even before a patient demonstrates any obvious symptoms, satisfying this huge unmet need.

Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through their subsidiary Zenon Biosystem. The estimated manufacturing cost per device is under $100 USD and possibly as low as $50 USD. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors". The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.

Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors. Both of these teams will fuse together through a high level advisory board of experienced professionals. A cost-effective Zenosense MRSA detection device, once developed, is expected to be in high demand, driven by patient safety, cost and insurance considerations. Disclaimer

Zenosense, Inc. Company Blog

Zenosense, Inc. News:

Zenosense, Inc. Update -- MRSA and Lung Cancer Device Development

Zenosense, Inc. Begins Development of Lung Cancer Detection Device

Zenosense, Inc. Highlights Recent Media Coverage of MRSA

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $10.50, up 5.00%, on 100 volume with 1 trade. The stock’s average daily volume over the past 60 days is 57, and its 52-week low/high is $5.00/$15.00.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.

AV-101, VistaGen's lead small molecule prodrug candidate, has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Receives Notice of Allowance for Canadian Patent, Further Expanding Stem Cell Technology Platform

VistaGen Announces Reverse Stock Split

VistaGen Receives Notice of Allowance for Canadian Patent Expanding Stem Cell Technology Platform

Vaporin, Inc. (VAPOD)

The QualityStocks Daily Newsletter would like to spotlight Vaporin, Inc. (VAPOD). Today, Vaporin, Inc. closed trading at $3.01, down 0.33%, on 12,086 volume with 18 trades. The stock’s average daily volume over the past 60 days is 53,350, and its 52-week low/high is $2.00/$12.50.

Vaporin, Inc. (VAPOD) distributes and markets vaporizers, e-liquids and e-hookah products. Leveraging a multi-pronged revenue model, the company’s growth strategy includes tapping into convenience store sales and online retail continuity programs as well as the acquisition and opening of brick and mortar retail stores.

Vaporin's flagship vapor technology offers the look, feel and taste of traditional cigarettes without any tar, tobacco, smoke and odor. Additionally, vaporizers offer a better quality experience with a more satisfying hit compared to e-cigarettes and have the ability to mix and match flavors. Due to these and other advantages, Bonnie Herzog, senior beverage and tobacco analyst at Wells Faro Securities, believes vapor consumption alone will surpass combustible cigarettes in the next decade.

The company’s vaporizing products can also be used to consume cannabis in oil, wax and dry herb form. Medical marijuana is now legalized in 23 states and the market is expected to grow by 64% this year to reach $2.34 billion in sales. Through an exclusive distribution agreement with Terra Tech Corp., Vaporin anticipates rapidly increasing the exposure of its brand in this rapidly growing market via an expanding dispensary network in California, Colorado, Washington and Oregon.

In just the past year the number of vape shops has increased more than 300% to over 30,000 stores, and the industry is projected to grow to $51 billion in 2030 by industry experts. Along with its other initiatives, Vaporin has plans to ambitiously grow their retail store model by continually acquiring existing stores as well as opening new locations. As a first mover primarily focused on this burgeoning market, the company is ideally positioned with a full line of products and e-liquids. Disclaimer

Vaporin, Inc. Company Blog

Vaporin, Inc. News:

UPDATE - Vaporin, Inc. Continues Expansion of The Vape Store Retail Locations

Why Vaporin, Inc Should be Trading Higher

Vaporin, Inc. Announces 1:50 Reverse Stock Split

WordLogic Corp. (WLGC)

The QualityStocks Daily Newsletter would like to spotlight WordLogic Corp. (WLGC). Today, WordLogic Corp. closed trading at $0.078, up 11.43%, on 650 volume with 1 trade. The stock’s average daily volume over the past 60 days is 59,289, and its 52-week low/high is $0.0601/$0.26.

WordLogic Corp. (WLGC) leverages more than 10 years of advanced R&D to assume its position as a global leader in predictive text input technology. Backed by multiple patents and its predictive engine, WordLogic’s interface is revolutionizing the way individuals and businesses search and communicate on touch screen devices. Furthermore, WordLogic offers a range of licensing options of its technology and patent portfolio.

The company’s technology incorporates proprietary Gesturing™ and WordChunking™ features that accelerate typing speeds while reducing the effort needed for accuracy. This interface increased text input on mobile devices by five times, rapidly speeding communication via instant messaging, text messaging, captioning, email and information searching. The iKnowU® keyboard uses state-of-the-art patented technology that becomes more accurate with each use, constantly learning about the user’s style and preferences. Utilizing the WordChunking and Gesturing, iKnowU enables the user to chain together phrases and create whole sentences in a matter of seconds.

For the business realm, WordLogic has developed a unique cloud solution to fit the specific needs of multiple industry sectors, enabling enterprises to create a single cloud-based dictionary specific to the company’s realm of expertise or multiple dictionaries specific for individual specialties or departments. This cloud solution creates continuity for users across multiple devices, boosting accuracy and productivity. WordLogic Reach™ enables users to select and insert meeting plans, contact information, and calendar entries from other apps in the mobile device.

Frost & Sullivan recently recognized WordLogic as the recipient of the 2014 North American Enabling Technology Leadership Award for Predictive Keyboard Applications, saying, “WordLogic’s technically impressive product - WordLogic Predictive Engine and its associated products iKnowU® and Reach™ - offers key competitive advantages, such as market-leading word and phrase prediction capabilities, a context-aware advertising model; simpler integration, increased speed and accuracy; and reduced costs. Add to that the significant number of pending and issued patents and you can see how value a package of technology WordLogic has developed truly is.” Disclaimer

WordLogic Corp. Company Blog

WordLogic Corp. News:

WordLogic the Sale of Exclusive Rights to Legal Enterprise Solutions to Private Equity Group

WordLogic Files Patent Infringement Lawsuit Against TouchType Ltd., Makers of SwiftKey

WordLogic Announces Development of iOS 8 Version of Award-Winning iKnowU Keyboard


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Pumps and Dumps


Real Pennies


Wall Street Resources

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251